Abstract
Background: Diagnosing patients with signs or symptoms suggestive of cancer is difficult. Serum tumor markers (TM) may be useful, but it is known that a range of pathologies other than cancer can increase their concentrations and so TM data must be interpreted with caution. The aim of this study is to determine the diagnostic accuracy of TMs in patients with signs or symptoms of cancer.
Methods: We prospectively studied 234 patients seen at rapid diagnostic units who presented signs or symptoms suggestive of cancer. Ninety patients had wasting syndrome, 74 had pulmonary symptoms and 70 other presentations. CYFRA21-1, CEA, CA19-9, total bilirubin and creatinine were determined. The final diagnosis was obtained after 6 months’ follow-up. Patients were classified according to the absence (group A) or presence (group B) of abnormal bilirubin or creatinine.
Results: Of the 234 patients studied, 103 (44.0%) had tumors diagnosed. Cut-off points for each TM were calculated for a specificity of 100%. For the total group, the values were CYFRA21-1, 15 μg/L, CEA, 43.8 μg/L and CA19-9, 7428 KU/L, with an overall sensitivity of 46.6%. For group A (n=142), the following cut-off points were established: CYFRA21-1, 7.8 μg/L, CEA, 13.8 μg/L and CA19-9, 101 KU/L, obtaining a sensitivity of 68.6%. For group B (n=92), the values were the same as for the whole group, and a sensitivity of 42.4% was achieved.
Conclusions: We conclude that TMs can aid diagnosis in these patients with signs or symptoms suggestive of cancer. Their sensitivity can be improved by using different cut-off points in the presence and absence of renal and hepatic dysfunction.
References
1. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11–79.10.1373/clinchem.2008.105601Search in Google Scholar
2. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer – European Group on Tumor Markers recommendations. Tumour Biol 2005;26:281–93.10.1159/000089260Search in Google Scholar
3. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441–7. Review.10.1093/annonc/mdp332Search in Google Scholar
4. Trape J, Montesinos J, Catot S, Buxo J, Franquesa J, Sala M, et al. A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer. Int J Biol Markers 2012;27:e257–62.10.5301/JBM.2012.9314Search in Google Scholar
5. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348–60. Review.10.1016/j.ejca.2007.03.021Search in Google Scholar
6. Mattar R, Alves de Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo 2002;57:89–92.10.1590/S0041-87812002000300001Search in Google Scholar
7. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990–2005.10.1016/S0959-8049(03)00547-1Search in Google Scholar
8. Trape J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer A, Rigo-Bonnin R; Oncology Section of the Catalan Association of Clinical Laboratory Science. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011;49:1605–20.10.1515/CCLM.2011.694Search in Google Scholar PubMed
9. Cases A, Filella X, Molina R, Ballesta AM, Lopez-Pedret J, Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991;57:183–6.10.1159/000186247Search in Google Scholar PubMed
10. Kashiwabara K, Kishi K, Nakamura H, Yagyu H, Kobayashi K, Watanabe O, et al. Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure. Intern Med 1998;37:917–21.10.2169/internalmedicine.37.917Search in Google Scholar PubMed
11. Bombardieri E, Seregni E, Bogni A, Ardit S, Belloli S, Busetto A, et al. Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: results of a multicenter trial. Int J Biol Markers 1994;9:89–95.10.1177/172460089400900205Search in Google Scholar
12. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989;13:123–33.10.1007/BF01806524Search in Google Scholar PubMed
13. Onal C, Colakoglu T, Ulusan SN, Yapar AF, Kayaselcuk F. Biliary obstruction induces extremely elevated serum CA 19-9 levels: case report. Onkologie 2012;35:780–2.10.1159/000345110Search in Google Scholar PubMed
14. Molina R, Bosch X, Auge JM, Filella X, Escudero JM, Molina V, et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumour Biol 2012;33:463–74.10.1007/s13277-011-0275-1Search in Google Scholar PubMed
©2015 by De Gruyter
